MicroPort Scientific critical care subsidiary MicroPort Surgical has acquired a 100% equity stake in German medical device manufacturer Hemovent for a total purchase value of up to $142.8m (€123m).

Established in 2013, Hemovent specialises in the development of Extracorporeal Life Support (ECLS) technology, often known as Extracorporeal Membrane Oxygenation (ECMO).

With the acquisition of Hemovent, MicroPort will be able to advance its strategy in emergency and critical care by combining Cardiopulmonary Bypass (CPB) with the research and development (R&D), manufacturing and commercialisation of ECMO products.

Additionally, the collaboration will develop a pipeline of products for offering systematic and integrated solutions in critical care.

MicroPort Surgery senior vice-president Seung-Kyun Yue said: “The products and technologies of Hemovent will complement the current portfolio of critical care solutions of MicroPort.

“After completion of the transaction, MicroPort will focus on strengthening its technology innovation and large-scale industrialisation capabilities in Germany, leveraging the synergy of global innovation resources to advance medical technology and save more patients’ lives worldwide.”

According to the Extracorporeal Life Support Organization (ELSO) guidelines, ECMO machines can be utilised for acute severe heart failure, cardiac and respiratory arrest, and acute severe respiratory failure, which have several causes.

ECMO reduces the cardiopulmonary burden in patients by providing continuous extracorporeal respiratory and circulatory support.

Hemovent’s Mobybox system is claimed to be the first fully-integrated ECLS system for the management of perfusion and gas exchange in a single device.

It has already obtained CE Mark and is commercially available in Europe.

The system does not require an external power supply, software or motors and can be operated only by pneumatics such as oxygen or compressed air.

It is intended to extend the device application from intensive care units to mobile medical scenarios.

The acquisition is anticipated to be completed in the fourth quarter of the year.